Efsubaglutide alfa
Based on 1 Customer Validation
Efsubaglutide alfa is a long-acting humanised GLP-1 receptor agonist. Efsubaglutide alfa binds specifically to the GLP-1 receptor, enhancing glucose-dependent insulin secretion, suppressing glucagon release, and promoting β-cell proliferation and increased β-cell mass. Efsubaglutide alfa improves glucose tolerance, increases pancreatic insulin content, and enhances β-cell secretory responses in isolated human islets. Efsubaglutide alfa reduces liver steatosis, lowers NAFLD Activity Scores, improves perisinusoidal collagen features, reduces serum ALT and AST levels, improves fasting glucose and triglyceride levels, and reduces body weight, liver weight and liver-to-body weight ratio. Efsubaglutide alfa can be used for the research of type 2 diabetes. Efsubaglutide alfa can be used for the research of metabolic dysfunction-associated steatohepatitis.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 95.67%
- CAS No.: 2803875-75-2
- 분자량:59.695 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Biological Activity
[GCG (glucagon) (Pr98-127)]2 - IGHG2 Fc
Human
GLP-1 receptor[1]
Efsubaglutide alfa enhances β-cell secretory responses, elevates β-cell proliferation, and increases β-cell mass in isolated human islets in culture[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (male, 18 weeks old, diet-induced obese, body weight >40 g)[2]
-
Dosage:0.290 mg/kg (low dose); 0.290 mg/kg (days 0-6) then 0.871 mg/kg (days 7-41) (medium dose); 0.290 mg/kg (days 0-6) then 0.871 mg/kg (days 7-13) then 1.306 mg/kg (days 14-41) (high dose)
-
Administration:s.c.; twice weekly; 41 days
-
Result:Reduced body weight by 18.93% (low dose), 25.54% (medium dose), 27.99% (high dose) by day 41.
Reduced liver weight and liver-to-body weight ratio across all doses; medium and high doses resulted in lower liver weights (839.4 mg and 839.7 mg, respectively) and liver-to-body weight ratios (2.53% and 2.64%, respectively) than semaglutide.
Decreased hepatic triglyceride (TG) and total cholesterol (TC) levels with low and high doses; reduced hepatic TG levels only with medium dose.
Reduced steatosis scores to 1.4 (low dose), 1.6 (medium dose), 1.3 (high dose).
Lowered NAFLD Activity Score (NAS) to 3.3 (low dose) and 3.0 (high dose) versus MASH controls' 4.5.
Reduced perisinusoidal collagen content (%PS) to 0.30% (low dose), 0.27% (medium dose), 0.30% (high dose) versus MASH controls' 0.40%.
Reduced the number of thin perisinusoidal collagen fibre bundles (ThinStrPS) to 8.99 (low dose), 7.99 (medium dose), 8.25 (high dose).
Reduced hepatic α-SMA expression with high dose.
Reduced serum alanine aminotransferase (ALT) levels to 54.4 U/L (low dose), 67.5 U/L (medium dose), 55.9 U/L (high dose).
Reduced serum aspartate aminotransferase (AST) levels to 101.0 U/L (low dose), 121.2 U/L (medium dose), 104.9 U/L (high dose).
Reduced fasting blood glucose to 6.19 mmol/L (low dose), 5.02 mmol/L (medium dose), 5.28 mmol/L (high dose); medium and high doses produced greater reductions than semaglutide.
Reduced serum insulin levels to 1.35 ng/mL (high dose).
Reduced serum TC, low-density lipoprotein cholesterol (LDL-c), and high-density lipoprotein cholesterol (HDL-c) levels across all doses; reduced serum TG levels with low and high doses.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
GLP1R
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
[PEPTIDE]2-FC
ELISA, FACS, Functional assay
-
Immobilized GLP1R Protein, Human (HEK293, N-His, C-Myc, HY-P700468) can bind Efsubaglutide alfa. The EC50 for this effect is 56.05 ng/mL.
Chemical Information
-
CAS No. 2803875-75-2
-
Appearance Liquid
-
분자량 59.695 kDa
-
Color Colorless to light yellow
-
SMILES
[Efsubaglutide alfa]
-
Synonyms
YN011; YN012; YN015
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
-
Data Sheet (263 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Jia W, Gao F, Lu J, Cheng Z, Dong X, Shi X, Su X, Li L, Zhang W, Wang Y, Ma J. Efsubaglutide alfa added to metformin improves glycaemia with β-cell functional responses in type 2 diabetes: a randomised, double-blind, placebo-controlled, two-stage adaptive phase 2b/3 trial (SUPER 2). Nature Communications. 2026 May 8. [Content Brief]
[2]. Wang Y, et al. Efsubaglutide Alfa attenuates metabolic dysfunction-associated steatohepatitis in mice with improvements in second harmonic generation-derived fibrosis features. Diabetes, obesity & metabolism. 2026 Apr;28(4):3070-3081. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Efsubaglutide alfa Related Classifications
HY-P990990 Related Classifications
Powered by Bioz